NEW YORK — Drug developer Sorrento Therapeutics said on Wednesday that it has licensed a rapid point-of-care SARS-CoV-2 test from Columbia University.
According to the San Diego-based company, the reverse transcription loop-mediated isothermal amplification (RT-LAMP)-based test involves placing a saliva or nasopharyngeal swab sample into a tube that is warmed in a heat block or water bath. A colorimetric readout is provided within 30 minutes, confirming the presence or absence of viral RNA.